Triebwasser Jourdan E, Higgins Stephanie, Secura Gina M, Zhao Qiuhong, Peipert Jeffrey F
Washington University in St. Louis School of Medicine Department of Obstetrics and Gynecology, Division of Clinical Research, 660 South Euclid Avenue Campus Box 8064, St. Louis, MO 63108, USA.
Washington University in St. Louis School of Medicine Department of Obstetrics and Gynecology, Division of Clinical Research, 660 South Euclid Avenue Campus Box 8064, St. Louis, MO 63108, USA.
Contraception. 2015 Jul;92(1):26-30. doi: 10.1016/j.contraception.2015.03.016. Epub 2015 Apr 7.
To compare self-reported 12-month continuation of oral contraceptive pills (OCPs), patch, and ring versus continuation by pharmacy claims data.
Women in the Contraceptive CHOICE Project who chose OCPs, the patch, or the ring as their initial method were included. Continuation was assessed by periodic telephone survey and by obtaining prescription claims data. Continuation was defined as no gap of more than 30 days. Kaplan-Meier survival functions were used to estimate continuation rates and cumulative unintended pregnancy rates. Kappa statistic assessed the level of agreement between self-report and claims data.
We analyzed 1510 women who initiated use by 3 months and provided information on discontinuation. Of OCP users, 59% continued their method at 12 months by self-report versus 38% by pharmacy claims. Patch and ring users had self-reported/pharmacy continuation of 45%/28% and 57%/37%, respectively. Kappa coefficients and their 95% confidence intervals between the two measurements were 0.46 (0.40, 0.52), 0.54 (0.39, 0.68), and 0.54 (0.47, 0.61) for OCP, patch, and ring, respectively. Among women who self-reported continuation, unintended pregnancy rates were 0.4% in those who continued by pharmacy claims versus 4.9% in those who discontinued according to claims data.
Contraceptive continuation rates differ by self-report versus pharmacy claims with women overestimating their continuation by self-report.
This article directly compares contraception continuation rates by self-report and by pharmacy claims data. The study suggests that previously reported continuation rates from survey data overestimate specific method use.
比较通过自我报告得出的口服避孕药(OCP)、避孕贴片和阴道避孕环的12个月持续使用情况与药房报销数据显示的持续使用情况。
纳入避孕选择项目中最初选择OCP、避孕贴片或阴道避孕环作为避孕方法的女性。通过定期电话调查和获取处方报销数据来评估持续使用情况。持续使用定义为中断时间不超过30天。采用Kaplan-Meier生存函数来估计持续使用率和累积意外妊娠率。Kappa统计量用于评估自我报告与报销数据之间的一致性水平。
我们分析了1510名在3个月内开始使用并提供了停药信息的女性。在OCP使用者中,自我报告显示12个月时59%的人持续使用该方法,而药房报销数据显示为38%。避孕贴片和阴道避孕环使用者自我报告/药房报销的持续使用率分别为45%/28%和57%/37%。OCP、避孕贴片和阴道避孕环两种测量方法之间的Kappa系数及其95%置信区间分别为0.46(0.40,0.52)、0.54(0.39,0.68)和0.54(0.47,0.61)。在自我报告持续使用的女性中,药房报销数据显示持续使用者的意外妊娠率为0.4%,而根据报销数据中断使用的女性意外妊娠率为4.9%。
避孕持续使用率在自我报告和药房报销数据之间存在差异,女性自我报告高估了她们的持续使用率。
本文直接比较了自我报告和药房报销数据得出的避孕持续使用率。该研究表明,先前调查数据报告的持续使用率高估了特定避孕方法的使用情况。